Researchers at the Institute for Systems Biology have developed a powerful new platform that can identify and deeply profile antigen-specific CD4+ T cells at unprecedented scale and resolution. Published in Nature Communications, the work could help accelerate vaccine design, improve immune monitoring, and advance next-generation cancer immunotherapies.
ISB researchers reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment
In a Research Roundtable presentation and Q&A, ISB President Dr. Jim Heath shared how his team is using generative AI to unlock new understanding of human immunity, and how these discoveries could help predict disease severity, improve cancer therapies, and more.
Co-Author Craig Mundie and ISB’s Dr. Jim Heath discuss AI’s rapid evolution, ethical considerations, and potential to revolutionize science and society in a compelling Town Hall event.
ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.